Tailoring antifungal doses for seniors: a precision approach

NCT ID NCT07496008

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find the best dose of isavuconazole, an antifungal drug, for patients over 60 with invasive fungal infections. Researchers will monitor drug levels in the blood and adjust doses to improve treatment and reduce side effects. The goal is to create personalized dosing guidelines for this older population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

isavuconazole

What this could lead to

If successful, this could lead to safer, more effective dosing guidelines for isavuconazole in older adults with invasive fungal infections.

What could go wrong

This is an early-stage observational study, not a large treatment trial. Results may not change current practice, and individual responses can vary widely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUCORMYCOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

invasive aspergillosis Zygomycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••